[KTP-80 laser endovaporisation of prostate symptomatic hypertrophy in patients under anticoagulant and/or antiagregant therapy].
Our population is ageing along with the rate of cardiovascular pathologies, which frequently require administration of antithrombotic treatments. Consequently, prostatic surgery becomes increasingly delicate. Thus per- and post-operative macroscopic hematuria contributes significantly to the duration of hospitalization and the morbidity of conventional surgery of symptomatic prostate hypertrophy. Moreover, these patients require transient suspension of their anticoagulation or anti-aggregation treatment. The recent KTP-80 laser limits post-operative hematuria and allows to operate on the growing population of patients under antiagregant and/or anticoagulant therapy. We review in these patients the operative modalities and the results of this surgery, in comparison with transurethral resection of the prostate.
Fateri
F
F
Département de chirurgie, HUG, Genève. Farshid.Fateri@hcuge.ch
Schwartz
J
J
Saaidia
A
A
Fleury
N
N
Tran
S Nam
SN
Hauser
J
J
Iselin
C
C
D000925:Anticoagulants / Q000627:therapeutic use; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006417:Hematuria / Q000517:prevention & control; D006760:Hospitalization; D006801:Humans; D053685:Laser Therapy / Q000295:instrumentation / Q000379:methods; D053844:Lasers, Solid-State / Q000627:therapeutic use*; D007902:Length of Stay; D008297:Male; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D019106:Postoperative Hemorrhage / Q000517:prevention & control; D011470:Prostatic Hyperplasia / Q000601:surgery*; D012449:Safety; D020728:Transurethral Resection of Prostate; D016896:Treatment Outcome
D000925:Anticoagulants; D005343:Fibrinolytic Agents; D010975:Platelet Aggregation Inhibitors